BiotechTube

Sunitinib Malate (SU011248)

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Conditions

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Trial Timeline

Nov 1, 2008 → Oct 1, 2014

NCT ID
NCT00793871

About Sunitinib Malate (SU011248)

Sunitinib Malate (SU011248) is a approved stage product being developed by Pfizer for Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00793871. Target conditions include Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors.

What happened to similar drugs?

6 of 20 similar drugs in Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors were approved

Approved (6) Terminated (4) Active (10)
🔄Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
✅Remimazolam TosilateJiangsu Hengrui MedicineApproved
❌Famitinib capsules + Sunitinib CapsulesJiangsu Hengrui MedicinePhase 3
🔄Esomeprazole IV + Omeprazole IVAstraZenecaPhase 3
🔄Durvalumab + FLOT chemotherapyAstraZenecaPhase 3
🔄EsomeprazoleAstraZenecaPhase 3
🔄EsomeprazoleAstraZenecaPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT00793871ApprovedCompleted
NCT00706706ApprovedCompleted
NCT00400569Phase 2Completed
NCT00457743Phase 1/2Completed

Competing Products

20 competing products in Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

See all competitors
ProductCompanyStageHype Score
Raludotatug Deruxtecan (R-DXd)Daiichi SankyoPhase 2
39
Patritumab deruxtecanDaiichi SankyoPhase 1/2
39
DS-6157aDaiichi SankyoPhase 1
21
DS-8201a + Physician's ChoiceDaiichi SankyoPhase 2
35
Naldemedine + PlaceboShionogiPhase 2
27
GemcitabineEli LillyPhase 1/2
32
OlaratumabEli LillyPhase 2
27
pemetrexed + cisplatinEli LillyPhase 2
35
cetuximabEli LillyPhase 2
35
BBI503Sumitomo PharmaPhase 2
27
BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + RegorafenibSumitomo PharmaPhase 1/2
32
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
40
Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol)Johnson & JohnsonPhase 2
35
Remimazolam TosilateJiangsu Hengrui MedicineApproved
43
Famitinib capsules + Sunitinib CapsulesJiangsu Hengrui MedicinePhase 3
32
FamitinibJiangsu Hengrui MedicinePhase 2
31
Esomeprazole IV + Omeprazole IVAstraZenecaPhase 3
40
Durvalumab + FLOT chemotherapyAstraZenecaPhase 3
44
EsomeprazoleAstraZenecaPhase 3
40
AZD2171AstraZenecaPhase 2
35